Radar reinforces the utility of AlloSure. Combined with the other recent publications on AlloSure clinical utility, Radar suggests a new standard for assessing AlloSure levels and reinforces the importance of monitoring changes in AlloSure levels over time. Buiding upon the most robust data repository of donor-derived cfDNA compiled transplantation, Radar two will be an extension of the Radar one study with a longer period of one year. Radar three will be an interventional study where AlloSure is used to guide adjustments in immunosuppression needed in patients with TCMR1A slash borderline changes. At two-point-nine percent, there is eighty-nine percent PPV for ABMR in DSA-positive patients. One percent is the threshold for active rejection. Zero-point-five percent is the delineation of biopsy-confirmed TCMR1A slash borderline rejections associated with adverse outcomes. At zero-point-two-one percent, there is ninety-five percent NPV for active rejection.